Medicilon USA Launches Second Research Facility in Massachusetts to Enhance Drug Development.
Medicilon USA Corp (Medicilon) has officially opened its second research and development (R&D) centre in Massachusetts. Located in Lexington, this new facility will focus on advanced animal models for pharmacokinetics/pharmacodynamics (PK/PD) and toxicology research, representing a major step forward in Medicilon’s global expansion strategy.
Enhancing Collaboration with Biotech Leaders
The choice of Lexington for the new R&D centre is strategic, aimed at boosting synergy with leading biotech firms and prominent research institutions. By situating the facility in this hub of innovation, Medicilon plans to deepen its engagement with industry experts and academic researchers. The Lexington centre is designed to offer crucial research services and support efficient communication with drug development teams both in industry and academia. Medicilon’s commitment to excellence in research will help its partners maintain a competitive edge as new therapeutic technologies continue to advance.
State-of-the-Art Facilities for Advanced Research
The new laboratory is equipped with cutting-edge technology and resources, significantly enhancing Medicilon’s R&D capabilities. It features advanced instrumentation and specialised animal laboratories, including a comprehensive library of animal models. This includes over 410 tumour efficacy models and more than 240 non-tumour target research models. The facility’s top-tier scientists will conduct efficacy evaluations for small molecule drugs and biologics, alongside pharmacokinetic studies and optimisation efforts. All research activities will adhere to rigorous international standards, including those set by ICH, NMPA, and FDA.
Since its initial U.S. expansion began in Boston in 2016, Medicilon has built a robust international collaborative network. The company started providing preclinical filing applications meeting both Chinese GLP and U.S. GLP standards. By 2023, Medicilon had already initiated local research projects with key U.S. partners. The new R&D centre in Massachusetts will greatly enhance Medicilon’s global service capabilities, reflecting its proactive approach to adapting to the evolving landscape of drug development.
Leveraging Boston’s Innovation Ecosystem
Dr Qingcong Lin, President of Medicilon USA, said, “Boston’s status as a leader in pharmaceutical innovation and technological advancement makes it an ideal location for our new research centre. We aim to capitalise on the local resources to unlock our full potential, enhance our technological capabilities, and explore new avenues in drug development through innovative partnerships.”
Advancement
Dr Chunlin Chen, Founder and CEO of Medicilon, added, “The launch of our Boston R&D centre strengthens our ties with the global pharmaceutical innovation ecosystem. We are dedicated to driving technological innovation and improving service quality, reinforcing our position as a trusted provider of preclinical research services on a global scale.”
This expansion marks a significant development in Medicilon’s mission to lead advancements in drug development and underscores its commitment to maintaining a leadership role in the global pharmaceutical research industry.
